A Phase 1 interventional study of linvoseltamab and dupilumab in Food Allergy, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.
Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 97th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 in phase 1, reaches primary completion later than 13 of the 27 other live ones, and was the 124th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Abigail Lang · Sites in United States
Ages 12–17
Stanford University · Sites in United States
Ages 4 mo–11 mo · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 1–30
Novartis Pharmaceuticals · Sites in United States
Ages 12–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 49 · Phase 3 7 · Phase 4 3
First in 1996; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 41 across the 105 interventional studies, 270 across the 33 observational. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 139 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
11 of the studies in Food Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06034678Children's National Research InstituteEvaluation of The Food Allergy Mastery Program | 2026-11-30 |
| NCT04222491Massachusetts General HospitalFood Oral Immunotherapy for Peanut Allergy | 2026-12 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05695261Rima RachidEvaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients | 2027-01-11 |
Add all 11 to your calendar (.ics) → With an account.
Among the 139 studies in Food Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE antibodies are sent out by cells like plasma cells. These antibodies and allergens bind to other cells that send out chemicals, causing an allergic reaction. The aim of the study is to see what side effects happen when linvoseltamab is combined with dupilumab.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: linvoseltamab · Drug: dupilumab
Administered by intravenous (IV) infusion
Also known as: REGN5458
Administered by subcutaneous (SC) injection
Also known as: Dupixent®, REGN668
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Severity of TEAEs
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Incidence of Adverse Event of Special Interest (AESIs)
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Severity of AESIs
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Incidence of Serious Adverse Events (SAEs)
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Severity of SAEs
Time frame: From the initial first dose of linvoseltamab through the end of week 30
Absolute change in the serum concentration of total IgE over time
Time frame: Baseline to the end of week 30
Percent change in the serum concentration of total IgE over time
Time frame: Baseline to the end of week 30
Time to reach unquantifiable total serum IgE concentration
Time frame: Through the end of week 30
Time to reach baseline level and/or the lower limit of the normal ranges of serum IgG
Time frame: Through the end of week 30
Time to reach baseline level and/or the lower limit of the normal ranges of serum immunoglobulin M (IgM)
Time frame: Through the end of week 30
Time to reach baseline level and/or the lower limit of the normal ranges of serum immunoglobulin A (IgA)
Time frame: Through the end of week 30
Incidence of participants with unquantifiable concentrations of serum total IgE
Time frame: Through the end of week 30
Absolute change in the serum concentration of food allergen-specific IgE
In participants who tested positive for a measured food allergen-specific IgE at baseline
Time frame: Baseline through the end of week 30
Percent change in the serum concentration of food allergen-specific IgE
In participants who tested positive for a measured food allergen-specific IgE at baseline
Time frame: Baseline through the end of week 30
Time to reach unquantifiable food allergen-specific serum IgE levels
In participants who tested positive for a measured food allergen-specific IgE at baseline
Time frame: Through the end of week 30
Incidence of TEAEs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Severity of TEAEs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Incidence of AESIs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Severity of AESIs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Incidence of SAEs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Severity of SAEs
Time frame: Following the combination study treatment period up to approximately 176 weeks
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Aug 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab